Effipride M 1mg/500mg Tablet PR
By Effipride M
Rx
10 Tablet PR in a Strip

Composition
Glimepiride(1mg) + Metformin(500mg)

Manufacturer - Efficus Life Sciences And Pharmaceuticals Pvt Ltd
TC:11/992-17, Temple Road Parottukonam, Nalanchira P O Trivandrum Thiruvananthapuram KL 695015 IN

Expires on or after
September, 2026

liver
When it comes to the use of Effipride M 1mg/500mg Tablet PR, caution is advised for individuals with liver disease. It may be necessary to adjust the dosage of Effipride M 1mg/500mg Tablet PR in such cases, so it is crucial to consult with your doctor before starting the medication. Typically, Effipride M 1mg/500mg Tablet PR is initiated at a low dose for patients with mild to moderate liver disease. However, it is not recommended for use in individuals with severe liver disease. It is important to follow your healthcare provider's guidance closely to ensure safe and effective use of this medication.

kidney
Effipride M 1mg/500mg Tablet PR should be used carefully in patients with kidney disease. Dose adjustment may be necessary. Avoid in severe kidney disease. Regular kidney function tests are recommended during treatment. Consult your doctor for guidance.

alcohol
It is not safe to mix alcohol with Effipride M 1mg/500mg Tablet PR.

driving
If you experience symptoms of low or high blood sugar, avoid driving while taking Effipride M 1mg/500mg Tablet PR to ensure safety.

pregnancy
Effipride M 1mg/500mg Tablet PR may be unsafe during pregnancy. Limited human studies suggest risks to the developing baby. Consult your doctor for a careful assessment of benefits and risks before using this medication.

breastfeeding
Caution Effipride M 1mg/500mg Tablet PR is not safe to use while breastfeeding as it may cause toxicity to the baby.
| Habit Forming | No |
| Chemical Class | Biguanide |
| Therapeutic Class | ANTI DIABETIC |
| Action Class | Sulfonylureas (Insulin Secretogogues) |
₹48.45
₹57
15% OFF
Inclusive of all taxes
Content verified by

Dr. Upasana Bhatia
MBBS - General Medicine
Last update on 01-Oct-2024
